Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for Illumina, Inc.�
0.00 (0.00%)
Mar 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 127.69 - 213.33
Open     -
Vol / Avg. 0.00/922,951.00
Mkt cap 26.51B
P/E 77.61
Div/yield     -
EPS 2.38
Shares 143.80M
Beta 0.80
Inst. own 95%
Apr 20, 2015
Q1 2015 Illumina Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 4, 2015
Illumina Inc at Cowen Health Care Conference
Jan 27, 2015
Q4 2014 Illumina Inc Earnings Call - Webcast
Jan 27, 2015
Q4 2014 Illumina Inc Earnings Release
Jan 12, 2015
Illumina Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 29.92% 18.98%
Operating margin 39.60% 27.65%
EBITD margin - 29.49%
Return on average assets 18.58% 11.11%
Return on average equity 44.92% 23.59%
Employees 3,700 -
CDP Score - -


5200 Illumina Way
SAN DIEGO, CA 92122-4616
United States - Map
+1-858-2024500 (Phone)
+1-858-2024766 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The Company is organized in two business segments: Life Sciences and Diagnostics. Its Life Sciences business unit includes all products and services related to the research market, namely the product lines based on its sequencing, BeadArray, VeraCode, and real-time PCR technologies. Its Diagnostics business unit focuses on molecular diagnostics. Its customers include genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies. In July 2014, the Company acquired Myraqa, a regulatory and quality consulting firm specializing in IVDs, particularly companion diagnostics.

Officers and directors

William H. Rastetter Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Francis A. deSouza President, Director
Age: 43
Bio & Compensation  - Reuters
Jay T. Flatley Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Marc A. Stapley Chief Financial Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
David R. Walt Ph.D. Chairman - Scientific Advisory Board, Independent Director
Age: 61
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Christian O. Henry Senior Vice President, Chief Compliance Officer
Age: 46
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Charles E. Dadswell Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Nicholas J. Naclerio Ph.D. Senior Vice President, Corporate Development & General Manager - Enterprise Informatics
Age: 41
Bio & Compensation  - Reuters
Tina S. Nova Ph.D. Senior Vice President, General Manager - Oncology
Age: 60
Bio & Compensation  - Reuters